{"id":"NCT00423085","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease","officialTitle":"A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Evaluation of the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease (MMSE 10-20)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01","primaryCompletion":"2009-03","completion":"2010-04","firstPosted":"2007-01-17","resultsPosted":"2011-05-25","lastUpdate":"2014-02-10"},"enrollment":859,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer's Disease"],"interventions":[{"type":"DRUG","name":"Rivastigmine transdermal patch","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"rivastigmine 5 cm^2","type":"EXPERIMENTAL"},{"label":"Rivastigmine 10 cm^2","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to investigate the 5cm\\^2 and 10cm\\^2 doses of rivastigmine transdermal patch in terms of efficacy and safety in patients with probable Alzheimer's Disease (MMSE \\[Mini Mental State Examination\\] 10-20). A 52-week extension phase evaluated the safety and tolerability of long-term treatment by rivastigmine transdermal patch in patients with probable Alzheimer's Disease (AD).","primaryOutcome":{"measure":"Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Placebo","deltaMin":24.8,"sd":9.46},{"arm":"Rivastigmine 5 cm^2","deltaMin":25.2,"sd":9.62},{"arm":"Rivastigmine 10 cm^2","deltaMin":25,"sd":9.93}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":286},"commonTop":["Application site erythema","Application site pruritus","Dermatitis contact","Nasopharyngitis","Application site oedema"]}}